SynerK is focused on developing innovative RNA-targeted medicines that aim to address significant medical needs. The company leverages advanced technologies in RNA biology to create therapies that can precisely modulate gene expression. This approach allows for the potential treatment of various diseases by targeting specific RNA molecules, thereby influencing the underlying biological processes involved in those conditions.

The company's pipeline includes a range of products that utilize these RNA-targeting technologies, showcasing their commitment to advancing therapeutic options. By harnessing the power of RNA, SynerK aims to engineer life-changing treatments that can improve patient outcomes and transform the landscape of medicine. Their research and development efforts are centered on creating effective solutions that are both safe and impactful for patients suffering from a variety of health issues.

United States

SynerK's founders are RNA-targeted therapy industry veterans with decades of drug development experience. Our expertise covers from discovery, preclinical and clinical development to commercial launch.

Millions suffer from life threatening diseases, yet only few benefits from current treatment. There is so much we understood but also much more to understand. We strive to find a way to treat disease where a genetic defect is present. One patient at a time, the number will add up.

SynerK

Company Details